National Vaccine and Serum Institute, China   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Beijing China (1919)
Status: No NME R&D (1919)

Organization Overview

First Clinical Trial
2019
NCT04083196
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

National Vaccine and Serum Institute, China

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Caliciviridae Infections (Phase 1)

Gastroenteritis (Phase 1)

Papillomavirus Infections (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 7